Neurology
Dementia Diagnostic Workup
NICE NG97 — cognitive assessment, exclude reversible causes, sub-type identification, support + medication, advance planning.
Source: NICE NG97 (2018)
Step 1 of ~8
info
Initial Assessment
Comprehensive history (informant essential): cognitive domains, daily functioning, behavioural change, time course, family history, vascular risk factors, alcohol, sleep, mood, medications. Cognitive screen: MoCA (preferred — sensitive to mild impairment), MMSE, Addenbrooke's. Examination: full neurological + cardiovascular + frailty assessment.
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Folinic Acid (Calcium Folinate / Leucovorin) · Antidote / Chemotherapy Support
- Tirzepatide · Dual GIP/GLP-1 Receptor Agonist — Type 2 Diabetes / Obesity
- Botulinum Toxin Type A (ENT) · Neuromuscular Blocking Agent (Botulinum Toxin)
- Enteral feeds · Nutritional support
- Donepezil · Acetylcholinesterase inhibitor (AChEI) — dementia
- Memantine · NMDA receptor antagonist — dementia
Pathways
- Acute Stroke / TIA Assessment · NICE NG128; RCP Stroke Guidelines 2023
- Status Epilepticus (Adults) · NICE CG137; ESEM guidelines; RCP Neurology Guidelines
- Suspected Subarachnoid Haemorrhage · NICE NG228; RCEM 2023; AHA/ASA 2023
- Adult Head Injury · NICE NG232 (2023)
- Bell's Palsy / Facial Nerve Palsy · ENT UK 2017; AAN
- Vertigo Workup · ENT UK; NICE CKS
Decision support only. Always apply local guidelines and clinical judgement.